ERBB2 and ovarian neoplasm: SPAG5 mRNA expression was lowest in wild-type (BRAF/KRAS/ERBB2) ovarian tumors, which differed from nonmutant tumors (P < 0.001) and wild-type (BRAF/KRAS) tumors (P < 0.001).